Table 4.
Results of multivariable regression analysis for association of statin use with in hospital mortality in patients with COVID 19.
| Odds ratios | 95% confidence interval | P-value | |
|---|---|---|---|
| Statins | 0.14 | 0.03 - 0.61 | 0.008 |
| Age | 2.2a | 1.3 - 3.8 | 0.004 |
| Neutrophil: lymphocyte ratio (NLR) | 1.58a | 1.05 - 2.38 | 0.028 |
| End stage renal disease | 27.1 | 2.08 - 353.6 | 0.012 |
| Intubation | 126.3 | 28.2 - 565.73 | <0.001 |
| Male gender | 1.6 | 0.45 - 5.49 | 0.482 |
| BMI | 0.99 | 0.91 - 1.08 | 0.908 |
| Hypertension | 0.66 | 0.11 - 3.95 | 0.654 |
| Diabetes mellitus | 1.7 | 0.47 - 6.24 | 0.412 |
| Coronary artery disease | 1.7 | 0.35 - 8.8 | 0.486 |
| Anti-platelets | 1.3 | 0.34 - 4.98 | 0.698 |
| ACEI/ARBs | 0.42 | 0.09–1.87 | 0.256 |
| Creatinine at admission | 0.7 | 0.54–1.03 | 0.079 |
Abbreviations: ACEI, Angiotensin converting enzyme inhibitor; ARB, Angiotensin receptor blocker; BMI, Body Mass Index.
a
Odds ratios for age and NLR are shown for increments of 10 for clinical relevance and ease of depiction.